Recurrent Islet Cell Carcinoma Completed Phase 1 Trials for Temsirolimus (DB06287)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01155258Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsTreatment